Salamanca woman jailed on murder, other charges
Breaking News
Salamanca woman jailed on murder, other charges
November 1, 2025
SALAMANCA — A city woman is facing murder and other felony charges after a death on River Street on Friday morning. The Salamanca Police Department re...
Home Online Features Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
Press Releases
Syndax Pharmaceuticals, Inc.  
November 15, 2024

Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation

– Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation

logo salamanca press

Salamanca Press

email salamanca press
Local & Social